Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Oncology Institute (DFPH) Revenue (2021 - 2025)

Historic Revenue for Oncology Institute (DFPH) over the last 5 years, with Q3 2025 value amounting to $136.6 million.

  • Oncology Institute's Revenue rose 3669.93% to $136.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $461.0 million, marking a year-over-year increase of 2166.77%. This contributed to the annual value of $393.4 million for FY2024, which is 2133.4% up from last year.
  • Per Oncology Institute's latest filing, its Revenue stood at $136.6 million for Q3 2025, which was up 3669.93% from $119.8 million recorded in Q2 2025.
  • In the past 5 years, Oncology Institute's Revenue registered a high of $136.6 million during Q3 2025, and its lowest value of $48.6 million during Q1 2021.
  • Over the past 5 years, Oncology Institute's median Revenue value was $80.2 million (recorded in 2023), while the average stood at $80.7 million.
  • In the last 5 years, Oncology Institute's Revenue surged by 3812.66% in 2023 and then skyrocketed by 1028.88% in 2025.
  • Oncology Institute's Revenue (Quarter) stood at $52.3 million in 2021, then soared by 36.56% to $71.4 million in 2022, then grew by 20.11% to $85.8 million in 2023, then grew by 16.88% to $100.3 million in 2024, then skyrocketed by 36.2% to $136.6 million in 2025.
  • Its last three reported values are $136.6 million in Q3 2025, $119.8 million for Q2 2025, and $104.4 million during Q1 2025.